文献速递白血病

UBTF串联重复定义成人新发急性髓系白血病的一种独特亚型

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.
PubMed 文献 · Leukemia · 2023-04-21

在1946例新诊断成人AML中筛查发现,UBTF串联重复(UBTF-TD)约占18-60岁患者的3%,与其他已知AML亚型定义性改变互斥。59例UBTF-TD成人AML特征为年轻(中位37岁)、骨髓原始细胞低浸润(中位25%)、WT1突变(61%)、FLT3-ITD(51%)及8号染色体三体(29%)高发。UBTF-TD患者完全缓解率低于UBTF野生型患者,3年无病生存率和总生存率与ELN 2022中危/高危患者无显著差异。

要点

  • UBTF-TD约占18-60岁成人新发AML的3%,与其他AML亚型定义性改变互斥。
  • UBTF-TD AML特征:年轻(中位37岁)、骨髓原始细胞低浸润(中位25%)、WT1突变61%、FLT3-ITD 51%、8号染色体三体29%。
  • UBTF-TD患者完全缓解率低于UBTF野生型,生存与ELN 2022中危/高危无显著差异。

核心结论

  • 本研究支持将UBTF-TD AML认定为成人AML的一个新实体。

研究设计与样本

  • 研究筛查了1946例新诊断成人AML,其中59例为UBTF-TD AML。
  • ALFA-0702研究纳入614例患者,包括21例UBTF-TD AML。

主要发现

  • UBTF-TD发生于约3%的18-60岁成人AML患者,与其他已知AML亚型定义性改变互斥。
  • 59例UBTF-TD成人AML特征:中位年龄37岁,骨髓原始细胞中位浸润25%,WT1突变61%,FLT3-ITD 51%,8号染色体三体29%。
  • 骨髓形态常显示粒系发育异常,但受FLT3-ITD共存影响。
  • UBTF-TD患者完全缓解率:1疗程强化化疗后57%,2疗程后76%,均低于UBTF野生型患者。
  • 在ALFA-0702研究中,UBTF-TD患者3年无病生存率42.9%(95%CI:23.4-78.5%),3年总生存率57.1%(95%CI:39.5-82.8%),与ELN 2022中危/高危患者无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF-TDs occur in about 3% of patients aged 18-60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF-TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1 mutations (61%), FLT3-ITDs (51%) and trisomy 8 (29%). BM morphology frequently demonstrates dysmyelopoiesis albeit modulated by the co-occurrence of FLT3-ITD. UBTF-TD patients have lower complete remission (CR) rates (57% after 1 course and 76% after 2 courses of intensive chemotherapy [ICT]) than UBTF-wild-type patients. In patients enrolled in the ALFA-0702 study (n = 614 patients including 21 with UBTF-TD AML), the 3-year disease-free survival (DFS) and overall survival of UBTF-TD patients were 42.9% (95%CI: 23.4-78.5%) and 57.1% (95%CI: 39.5-82.8%) and did not significantly differ from those of ELN 2022 intermediate/adverse risk patients. Finally, the study of paired diagnosis and relapsed/refractory AML samples suggests that WT1-mutated clones are frequently selected under ICT. This study supports the recognition of UBTF-TD AML as a new AML entity in adults.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Duployez N, Vasseur L, Kim R, et al. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia. Leukemia. 2023. PMID: 37085611. doi:10.1038/s41375-023-01906-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。